John Chan, MD
Gynecologic Oncology · San Francisco, CANPI 1962596551
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,507,609 of the $1,980,546 with a category attached, or 76.1%. 23 manufacturers reported payments, led by AstraZeneca at 30.6% of the total. Among gynecologic oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,383 payments — averaging $1432.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$605K
- GSK$553K
- Eisai Inc.$216K
- Tesaro, Inc.$101K
- Merck$94K
- Clovis Oncology, Inc.$83K
- plus $328K from 17 others
Across 119 payments — averaging $9483.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$541K
- GSK$134K
- Novocure Inc.$109K
- Takeda Pharmaceuticals U.S.A., Inc.$73K
- Genentech, Inc.$71K
- Pfizer$60K
- plus $140K from 7 others
What the payments were for
- Consulting fees$245,01012%
- Speaking & faculty fees$1,507,60976%
- Travel & lodging$192,80810%
- Food & beverage$34,1672%
- Education$9520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 380 | $605,274 |
| GSK | 316 | $553,027 |
| Eisai Inc. | 147 | $216,478 |
| Tesaro, Inc. | 120 | $100,994 |
| Merck | 106 | $93,727 |
| Clovis Oncology, Inc. | 85 | $82,698 |
| Seagen Inc. | 41 | $75,223 |
| AbbVie | 40 | $73,843 |
| Genmab U.S., Inc. | 36 | $66,738 |
| Pfizer | 28 | $46,753 |
| Genentech USA, Inc. | 15 | $18,781 |
| Immunogen, Inc. | 14 | $18,425 |
| F. Hoffmann-la Roche AG | 7 | $18,199 |
| Myriad Genetic Laboratories, Inc. | 26 | $5,959 |
| Medical Device Business Services, Inc. | 4 | $1,916 |
| Eisai CO., LTD. | 1 | $1,226 |
| Corcept Therapeutics | 5 | $440 |
| Johnson & Johnson | 6 | $317 |
| Epizyme, Inc. | 2 | $225 |
| Intuitive Surgical | 1 | $126 |
| Karyopharm Therapeutics Inc. | 1 | $103 |
| Eli Lilly | 1 | $57 |
| Medtronic | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$601,421
- ZEJULA$398,473
- JEMPERLI$233,931
- LENVIMA$216,785
- TIVDAK$172,899
- Elahere$86,736
- Rubraca$81,946
- GARDASIL$64,786
- KEYTRUDA$24,289
- Avastin$18,558
- TECENTRIQ$18,199
- myChoice CDx$5,179
- GARDASIL 9$3,355
- EPKINLY$2,400
- Harmonic$240
- PreciseTumor$234
- DERMABOND$131
- STRATAFIX$131
- Da Vinci Surgical System$126
- TAZVERIK$125
How this compares
$1,980,546 in reported general payments places this provider in the 95th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 11 | $506 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 48 | $156 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in San Francisco
- Katherine FuhSan Francisco$26K
- Lejla DelicSan Francisco$16K
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
- Kenneth KimWest Hollywood$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.